PARP1 and breast carcinoma: Differences in the metabolic signature between cell lines harboring different DNA repair mutations and measuring their response to PARP inhibitors can inform the rationale for selecting PARP inhibitors in certain breast cancer types and explore potential additional vulnerabilities as druggable targets [18].